Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Other Non-Current Liabilities (2016 - 2024)

VYNE Therapeutics (VYNE) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $1.3 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Other Non-Current Liabilities rose 537.38% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Mar 2024, up 537.38%, and an annual FY2023 reading of $1.3 million, up 537.38% over the prior year.
  • Other Non-Current Liabilities was $1.3 million for Q1 2024 at VYNE Therapeutics, roughly flat from $1.3 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $1.3 million in Q4 2023 and bottomed at $206000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $440866.7, with a median of $312000.0 recorded in 2020.
  • The sharpest move saw Other Non-Current Liabilities crashed 54.82% in 2021, then soared 537.38% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $312000.0 in 2020, then tumbled by 33.97% to $206000.0 in 2021, then changed by 0.0% to $206000.0 in 2022, then skyrocketed by 537.38% to $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024.
  • Business Quant data shows Other Non-Current Liabilities for VYNE at $1.3 million in Q1 2024, $1.3 million in Q4 2023, and $206000.0 in Q1 2023.